Compare POAI & PTIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | POAI | PTIX |
|---|---|---|
| Founded | 2002 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5M | 6.3M |
| IPO Year | N/A | 2016 |
| Metric | POAI | PTIX |
|---|---|---|
| Price | $5.55 | $1.69 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 27.4K | ★ 75.8K |
| Earning Date | 11-14-2025 | 11-26-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,664,407.00 | N/A |
| Revenue This Year | $486.27 | N/A |
| Revenue Next Year | $65.50 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 320.71 | N/A |
| 52 Week Low | $4.76 | $1.65 |
| 52 Week High | $45.90 | $14.28 |
| Indicator | POAI | PTIX |
|---|---|---|
| Relative Strength Index (RSI) | 35.22 | 30.61 |
| Support Level | $5.31 | $1.84 |
| Resistance Level | $6.00 | $2.38 |
| Average True Range (ATR) | 0.55 | 0.19 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 7.16 | 9.46 |
Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's main compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.